# Blood Bank Inventory Management Operations

## Overview
Blood bank operations managing blood product inventory, compatibility testing, transfusion safety, and regulatory compliance using Laboratory Information Systems with integrated blood bank modules.

## 1. Blood Product Receipt and Inspection

### Shipment Verification
**Annotation**: Incoming <entity type="shipment">blood product shipments</entity> from <entity type="supplier">regional blood centers</entity> require verification of <entity type="data">shipping temperature logs</entity> (maintained at <entity type="temp">1-10°C</entity> for <entity type="product">red blood cells</entity>, <entity type="temp">20-24°C</entity> for <entity type="product">platelets</entity>), <entity type="document">packing slips</entity>, <entity type="identifier">unit numbers</entity>, <entity type="identifier">product codes</entity>, and <entity type="identifier">expiration dates</entity> per <entity type="standard">AABB Standards</entity>.

### Unit Inspection and Quarantine
**Annotation**: Each <entity type="unit">blood unit</entity> undergoes <entity type="inspection">visual inspection</entity> checking for <entity type="defect">discoloration</entity>, <entity type="defect">clots</entity>, <entity type="defect">hemolysis</entity>, <entity type="defect">abnormal appearance</entity>, and <entity type="defect">bag integrity</entity>, with <entity type="action">questionable units</entity> placed in <entity type="status">quarantine status</entity> within the <entity type="system">LIS blood bank module</entity> preventing <entity type="prevention">accidental issue</entity> until <entity type="resolution">medical director review</entity>.

### Inventory Recording
**Annotation**: Upon receipt, <entity type="system">blood bank LIS systems</entity> like <entity type="vendor">Ortho Vision</entity>, <entity type="vendor">Immucor Galileo</entity>, or <entity type="vendor">Haemonetics BloodTrack</entity> scan <entity type="identifier">ISBT 128 barcodes</entity> encoding <entity type="data">donation identification number</entity>, <entity type="data">product code</entity>, <entity type="data">ABO/Rh type</entity>, <entity type="data">collection date</entity>, and <entity type="data">expiration date</entity>, automatically updating <entity type="inventory">available inventory</entity> by <entity type="category">product type</entity> and <entity type="category">blood type</entity>.

## 2. ABO/Rh Typing and Antibody Screening

### Forward and Reverse Grouping
**Annotation**: <entity type="test">ABO typing</entity> requires both <entity type="method">forward grouping</entity> (testing <entity type="sample">patient red cells</entity> with <entity type="reagent">anti-A</entity> and <entity type="reagent">anti-B antibodies</entity>) and <entity type="method">reverse grouping</entity> (testing <entity type="sample">patient serum</entity> with <entity type="reagent">A1 and B red cells</entity>), with <entity type="requirement">concordant results</entity> confirming <entity type="result">ABO type</entity> per <entity type="standard">AABB Technical Manual</entity> requirements.

### Rh Typing and Weak D Testing
**Annotation**: <entity type="test">Rh typing</entity> tests <entity type="sample">patient red cells</entity> with <entity type="reagent">anti-D antibodies</entity>, with <entity type="result">negative immediate spin reactions</entity> requiring <entity type="followup">weak D (Du) testing</entity> using <entity type="method">indirect antiglobulin technique</entity> to detect <entity type="variant">weak D phenotypes</entity> important for <entity type="population">transfusion recipients</entity> (treated as <entity type="classification">Rh-negative</entity>) versus <entity type="population">pregnant patients</entity> (treated as <entity type="classification">Rh-positive</entity> for <entity type="intervention">RhIG administration decisions</entity>).

### Antibody Screening and Identification
**Annotation**: <entity type="test">Antibody screens</entity> detect <entity type="target">unexpected alloantibodies</entity> by incubating <entity type="sample">patient serum</entity> with <entity type="reagent">screening cells</entity> (2-3 group O cells with known antigens), with <entity type="result">positive screens</entity> requiring <entity type="workup">antibody identification</entity> using <entity type="panel">antibody identification panels</entity> (8-16 cells) to determine <entity type="specificity">antibody specificity</entity> like <entity type="examples">anti-Kell, anti-Duffy, anti-Kidd</entity> affecting <entity type="selection">compatible unit selection</entity>.

## 3. Crossmatching Procedures

### Electronic Crossmatch Eligibility
**Annotation**: <entity type="method">Electronic crossmatch</entity> (also called <entity type="synonym">computer crossmatch</entity>) is permitted for <entity type="patient">patients without clinically significant antibodies</entity> when the <entity type="system">blood bank computer system</entity> has <entity type="verification">two independent ABO/Rh determinations</entity> documented, <entity type="verification">current negative antibody screen</entity>, and performs <entity type="check">ABO compatibility verification</entity> between <entity type="donor">donor unit</entity> and <entity type="recipient">recipient</entity> per <entity type="standard">AABB Standards 5.14</entity>.

### Serologic Crossmatch
**Annotation**: When <entity type="criteria">electronic crossmatch criteria</entity> are not met, <entity type="method">serologic crossmatch</entity> (also called <entity type="synonym">major crossmatch</entity>) mixes <entity type="sample">patient serum</entity> with <entity type="sample">donor red cells</entity> using <entity type="technique">immediate spin</entity> and <entity type="technique">indirect antiglobulin test (IAT)</entity> phases detecting <entity type="incompatibility">ABO incompatibility</entity> and <entity type="incompatibility">unexpected antibodies</entity> ensuring <entity type="safety">serologic compatibility</entity> before <entity type="transfusion">transfusion</entity>.

### Crossmatch-to-Transfusion Ratio
**Annotation**: <entity type="metric">C:T ratio</entity> comparing <entity type="numerator">units crossmatched</entity> to <entity type="denominator">units transfused</entity> is monitored as a <entity type="indicator">blood utilization indicator</entity>, with <entity type="target">target ratios < 2.5</entity> for <entity type="procedure">routine surgical procedures</entity> indicating <entity type="assessment">appropriate ordering practices</entity>, while <entity type="high_ratio">elevated ratios</entity> suggest <entity type="issue">excessive crossmatching</entity> warranting <entity type="intervention">type and screen protocols</entity> implementation.

## 4. Inventory Management and Rotation

### FIFO and FEFO Strategies
**Annotation**: <entity type="principle">First-In-First-Out (FIFO)</entity> manages <entity type="product">non-expiring inventory categories</entity> while <entity type="principle">First-Expire-First-Out (FEFO)</entity> manages <entity type="product">blood components</entity> with varying <entity type="attribute">expiration dates</entity>, with <entity type="system">LIS algorithms</entity> automatically selecting <entity type="unit">oldest appropriate units</entity> for <entity type="process">crossmatching</entity> and <entity type="process">issue</entity> minimizing <entity type="waste">product outdates</entity>.

### Emergency Release Protocols
**Annotation**: <entity type="scenario">Massive hemorrhage protocols</entity> allow <entity type="process">emergency release</entity> of <entity type="product">uncrossmatched blood</entity> with <entity type="type">O-negative RBCs</entity> for <entity type="patient">any patient</entity>, <entity type="type">O-positive RBCs</entity> for <entity type="patient">male patients or females beyond childbearing age</entity>, and <entity type="type">AB plasma</entity> as <entity type="designation">universal plasma</entity>, documented with <entity type="form">emergency release forms</entity> signed by <entity type="authority">requesting physician</entity> acknowledging <entity type="risk">potential incompatibility</entity> per <entity type="standard">AABB Standards 5.18</entity>.

### Critical Inventory Alerts
**Annotation**: <entity type="system">Inventory management systems</entity> generate <entity type="alert">critical inventory alerts</entity> when <entity type="stock">available units</entity> fall below <entity type="threshold">minimum par levels</entity> (typically <entity type="duration">2-day supply</entity>) for <entity type="category">each blood type</entity>, triggering <entity type="action">emergency orders</entity> from <entity type="supplier">blood suppliers</entity>, <entity type="action">inventory borrowing</entity> from <entity type="partner">neighboring facilities</entity>, or <entity type="action">surgical schedule adjustments</entity> to conserve inventory.

## 5. Special Product Management

### Irradiated Blood Products
**Annotation**: <entity type="process">Gamma or X-ray irradiation</entity> of <entity type="product">blood components</entity> at <entity type="dose">25 Gy (2500 rads)</entity> prevents <entity type="complication">transfusion-associated graft-versus-host disease (TA-GVHD)</entity> in <entity type="population">immunocompromised recipients</entity>, <entity type="population">hematopoietic stem cell transplant patients</entity>, and <entity type="population">directed donations from blood relatives</entity>, with <entity type="label">irradiation labels</entity> and <entity type="expiration">reduced shelf life</entity> (<entity type="duration">28 days post-irradiation for RBCs</entity>) documented in <entity type="system">LIS</entity>.

### Leukoreduced Products
**Annotation**: <entity type="process">Leukoreduction</entity> removes <entity type="target">white blood cells</entity> to <entity type="level">< 5 × 10⁶ residual leukocytes</entity> per unit preventing <entity type="complication">febrile non-hemolytic transfusion reactions</entity>, <entity type="complication">HLA alloimmunization</entity>, and <entity type="complication">CMV transmission</entity>, performed via <entity type="method">filtration</entity> either <entity type="timing">pre-storage</entity> (by <entity type="source">blood center</entity>) or <entity type="timing">bedside</entity> (using <entity type="device">leukoreduction filters</entity>), with <entity type="validation">routine QC</entity> confirming <entity type="performance">adequate leukocyte reduction</entity>.

### Washed and Volume-Reduced Products
**Annotation**: <entity type="process">Cell washing</entity> removes <entity type="removal">plasma proteins</entity>, <entity type="removal">antibodies</entity>, and <entity type="removal">potassium</entity> preventing <entity type="reaction">allergic reactions</entity> in <entity type="patient">IgA-deficient patients</entity> or severe reactions to <entity type="component">plasma components</entity>, while <entity type="process">volume reduction</entity> concentrates <entity type="product">platelets</entity> for <entity type="patient">neonates</entity> or <entity type="patient">volume-overload-risk patients</entity>, with <entity type="expiration">4-hour expiration</entity> post-manipulation requiring <entity type="coordination">just-in-time preparation</entity>.

## 6. Platelet Management

### Platelet Inventory Challenges
**Annotation**: <entity type="product">Platelets</entity> have <entity type="limitation">5-day shelf life</entity> and require <entity type="storage">room temperature storage</entity> with <entity type="agitation">continuous agitation</entity> creating <entity type="challenge">inventory management challenges</entity>, addressed through <entity type="strategy">demand forecasting algorithms</entity>, <entity type="strategy">platelet pheresis collection scheduling</entity>, and <entity type="strategy">inter-facility sharing agreements</entity> balancing <entity type="goal">product availability</entity> with <entity type="goal">outdate minimization</entity>.

### ABO Compatibility Considerations
**Annotation**: While <entity type="transfusion">platelet transfusions</entity> prioritize <entity type="match">ABO-identical products</entity>, <entity type="practice">ABO-incompatible platelets</entity> are clinically acceptable due to <entity type="cells">low red cell contamination</entity>, though <entity type="consideration">minor incompatibility</entity> (patient plasma incompatible with donor RBCs) is preferred over <entity type="consideration">major incompatibility</entity> (patient RBCs incompatible with donor plasma) to avoid <entity type="complication">hemolytic reactions</entity> from <entity type="antibodies">high-titer anti-A/anti-B</entity> in <entity type="product">plasma-rich platelet products</entity>.

### Bacterial Contamination Testing
**Annotation**: <entity type="risk">Bacterial contamination</entity> is the <entity type="impact">leading infectious complication</entity> of <entity type="product">platelet transfusion</entity> due to <entity type="storage">room temperature storage</entity>, requiring <entity type="mitigation">bacterial detection methods</entity> including <entity type="method">culture-based testing</entity> (at <entity type="timing">24-36 hours post-collection</entity>) or <entity type="method">rapid bacterial detection</entity> (before <entity type="timing">issue</entity>) using <entity type="technology">Gram stain</entity>, <entity type="technology">flow cytometry</entity>, or <entity type="technology">immunoassays</entity> per <entity type="requirement">FDA and AABB requirements</entity>.

## 7. Massive Transfusion Protocols

### MTP Activation Criteria
**Annotation**: <entity type="protocol">Massive Transfusion Protocols (MTP)</entity> are activated for <entity type="patient">patients requiring ≥ 10 units RBCs in 24 hours</entity> or <entity type="patient">≥ 4 units in 1 hour</entity>, automatically triggering <entity type="delivery">pre-defined blood product packages</entity> (typically <entity type="ratio">1:1:1 RBC:FFP:platelets</entity>) delivered to <entity type="location">trauma bays</entity> or <entity type="location">operating rooms</entity> at <entity type="frequency">fixed intervals</entity> without individual <entity type="process">crossmatch requests</entity>, reducing <entity type="goal">transfusion delays</entity>.

### Hemostatic Resuscitation Principles
**Annotation**: <entity type="approach">Damage control resuscitation</entity> emphasizes <entity type="principle">early plasma and platelet administration</entity> in <entity type="ratio">balanced ratios</entity> (<entity type="ratio">1:1:1 or 1:1:2</entity>), <entity type="principle">restrictive crystalloid</entity>, <entity type="principle">permissive hypotension</entity> until <entity type="milestone">hemorrhage control</entity>, and <entity type="adjunct">adjunct hemostatic agents</entity> (<entity type="medication">tranexamic acid</entity>, <entity type="product">fibrinogen concentrate</entity>, <entity type="product">prothrombin complex concentrates</entity>) following <entity type="evidence">military and civilian trauma evidence</entity>.

### Massive Transfusion Documentation
**Annotation**: <entity type="system">Blood bank LIS</entity> maintains <entity type="record">MTP activation logs</entity> documenting <entity type="data">activation time</entity>, <entity type="data">activating physician</entity>, <entity type="data">patient location</entity>, <entity type="data">products issued</entity> by <entity type="data">package number</entity>, <entity type="data">deactivation time</entity>, and <entity type="data">unused product return</entity>, supporting <entity type="review">quality review</entity> of <entity type="metric">appropriate MTP activations</entity> and <entity type="metric">product utilization patterns</entity>.

## 8. Donor Exposure Tracking

### Transfusion Recipient Records
**Annotation**: <entity type="system">Blood bank systems</entity> maintain <entity type="link">recipient-donation linkage</entity> associating each <entity type="transfusion">transfused unit</entity> with <entity type="recipient">recipient medical record number</entity>, <entity type="datetime">transfusion date/time</entity>, <entity type="location">transfusion location</entity>, and <entity type="provider">transfusing provider</entity>, enabling <entity type="capability">donor lookback</entity> and <entity type="capability">recipient tracing</entity> for <entity type="event">post-donation information</entity> or <entity type="event">transfusion-transmitted infections</entity>.

### Lookback Investigations
**Annotation**: When a <entity type="donor">blood donor</entity> subsequently tests positive for <entity type="disease">transfusion-transmissible infections</entity> (<entity type="pathogen">HIV</entity>, <entity type="pathogen">HCV</entity>, <entity type="pathogen">HBV</entity>), <entity type="process">lookback procedures</entity> identify <entity type="recipients">recipients of prior donations</entity> within <entity type="window">defined lookback periods</entity>, notify <entity type="stakeholders">recipients and physicians</entity>, recommend <entity type="testing">confirmatory testing</entity>, and report to <entity type="authorities">public health authorities</entity> per <entity type="regulation">FDA regulations 21 CFR 610.46-47</entity>.

### Hemovigilance Reporting
**Annotation**: <entity type="program">Hemovigilance programs</entity> systematically monitor and report <entity type="event">adverse transfusion reactions</entity> including <entity type="reaction">hemolytic reactions</entity>, <entity type="reaction">TRALI</entity>, <entity type="reaction">TACO</entity>, <entity type="reaction">allergic reactions</entity>, and <entity type="reaction">septic reactions</entity> to <entity type="system">institutional blood utilization committees</entity> and <entity type="registry">national registries</entity> like <entity type="program">AABB Hemovigilance Program</entity> or <entity type="program">National Healthcare Safety Network (NHSN)</entity> improving <entity type="goal">transfusion safety</entity>.

## 9. Quality Control and Proficiency Testing

### Daily Equipment QC
**Annotation**: <entity type="equipment">Blood bank refrigerators</entity>, <entity type="equipment">freezers</entity>, <entity type="equipment">platelet incubators</entity>, and <entity type="equipment">centrifuges</entity> undergo <entity type="frequency">daily temperature monitoring</entity>, with <entity type="range">refrigerators 1-6°C</entity>, <entity type="range">freezers ≤ -18°C</entity>, <entity type="range">platelet incubators 20-24°C</entity>, and <entity type="alarm">automatic alarm systems</entity> alerting for <entity type="deviation">out-of-range conditions</entity> requiring <entity type="action">corrective actions</entity> and <entity type="documentation">documentation</entity> per <entity type="standard">AABB Standards 5.1.8</entity>.

### Reagent and Equipment Validation
**Annotation**: New <entity type="reagent">reagent lots</entity> and <entity type="equipment">equipment</entity> require <entity type="validation">validation</entity> using <entity type="control">positive and negative controls</entity> before <entity type="use">clinical use</entity>, with <entity type="criteria">acceptable performance</entity> documented in <entity type="system">QC logs</entity>, while <entity type="validation">annual proficiency testing</entity> through <entity type="provider">CAP</entity> or <entity type="provider">AABB programs</entity> evaluates <entity type="performance">technologist competency</entity> and <entity type="performance">testing accuracy</entity>.

### Transfusion Reaction Investigation
**Annotation**: Suspected <entity type="event">transfusion reactions</entity> trigger <entity type="protocol">immediate investigation</entity> including <entity type="check">clerical checks</entity> verifying <entity type="match">correct unit-patient association</entity>, <entity type="test">visual inspection</entity> of <entity type="sample">post-transfusion samples</entity> for <entity type="sign">hemolysis</entity> or <entity type="sign">hemoglobinuria</entity>, <entity type="test">repeat ABO/Rh and DAT</entity>, and <entity type="culture">bacterial cultures</entity> for <entity type="reaction">suspected septic reactions</entity>, with <entity type="report">investigation reports</entity> documenting <entity type="findings">findings</entity> and <entity type="actions">preventive actions</entity>.

## 10. Regulatory Compliance

### FDA Blood Establishment Registration
**Annotation**: <entity type="facility">Hospital blood banks</entity> performing <entity type="activity">compatibility testing</entity> must register with <entity type="agency">FDA</entity> as <entity type="classification">blood establishments</entity> under <entity type="regulation">21 CFR Part 607</entity>, comply with <entity type="regulation">cGMP requirements (21 CFR Part 606)</entity>, maintain <entity type="records">required records</entity> for <entity type="retention">10 years</entity>, and report <entity type="event">biological product deviations</entity> and <entity type="event">fatalities</entity> per <entity type="regulation">21 CFR Part 606.171</entity>.

### AABB Accreditation
**Annotation**: <entity type="accreditation">AABB accreditation</entity> requires compliance with <entity type="standards">AABB Standards for Blood Banks and Transfusion Services</entity> covering <entity type="domain">facilities</entity>, <entity type="domain">personnel</entity>, <entity type="domain">equipment</entity>, <entity type="domain">supplier qualification</entity>, <entity type="domain">process control</entity>, <entity type="domain">testing</entity>, <entity type="domain">compatibility</entity>, <entity type="domain">distribution</entity>, <entity type="domain">storage</entity>, and <entity type="domain">quality systems</entity>, verified through <entity type="process">on-site inspections</entity> every <entity type="frequency">2 years</entity>.

### State Regulations
**Annotation**: Many <entity type="jurisdiction">states</entity> require separate <entity type="license">state blood bank licenses</entity> with <entity type="inspection">state inspections</entity> in addition to <entity type="federal">federal requirements</entity>, with states like <entity type="example">California</entity>, <entity type="example">New York</entity>, and <entity type="example">Pennsylvania</entity> having particularly <entity type="stringency">stringent regulations</entity> governing <entity type="scope">blood bank operations</entity>, <entity type="scope">personnel qualifications</entity>, and <entity type="scope">quality requirements</entity>.

## Vendor Systems

- **Blood Bank LIS**: Ortho Vision, Immucor Galileo, Grifols Erytra Eflexis, Haemonetics BloodTrack
- **Automated Testing**: Ortho AutoVue Innova, Immucor NEO, Grifols Erytra, Bio-Rad IH-1000
- **Inventory Management**: Haemonetics BloodTrack, Fresenius Kabi SafeTrace Tx
- **Blood Irradiators**: Best Theratronics Raycell, Rad Source RS-3400, Hitachi Gammacell
- **Reagent Manufacturers**: Ortho Clinical Diagnostics, Immucor, Grifols, Bio-Rad, Quotient

## Standards and Regulations

- **AABB Standards**: Technical standards for blood banks and transfusion services
- **FDA 21 CFR**: Parts 600-680 (biologics regulations), Part 606 (cGMP), Part 607 (establishment registration)
- **AABB Technical Manual**: Reference for blood bank procedures and practices
- **CAP**: Blood bank/transfusion service inspection checklists
- **Joint Commission**: Medication management and transfusion standards
- **CLIA**: Laboratory certification for transfusion services
